Last updated: February 27, 2026
What is the scope of patent PL2881109?
Patent PL2881109 pertains to a specific drug formulation, method, or use. The patent's scope is defined by its claims, which establish the legal boundary of exclusivity. The patent was filed, granted, and detailed under Polish patent law, with potential extensions or equivalents in other jurisdictions.
The patent primarily covers a pharmaceutical composition comprising an active ingredient, possibly combined with excipients, or a method of treating a specific condition. It likely emphasizes a novel aspect of formulation, delivery, or manufacturing process, especially if it provides improved stability, bioavailability, or therapeutic efficacy.
What are the main claims of PL2881109?
The claims of patent PL2881109 specify the unique aspects that differentiate it from prior art. As of the latest records, the patent contains:
- Independent claims: Covering the core invention, such as a pharmaceutical composition with particular characteristics or a method of treatment using the composition.
- Dependent claims: Detailing specific embodiments, such as the inclusion of certain excipients, dosing regimens, or formulations.
Typical claim language might include:
- A composition comprising an active ingredient at a specific concentration.
- A method of preparing said composition.
- A therapeutic use of the composition in treating a particular disease.
The scope is limited to these claims, which are supported by detailed disclosure describing the invention, preferred embodiments, and examples.
What does the patent landscape for this drug look like?
European and International Patent Activity
- European Patent Office (EPO): Similar or equivalent patents filed under the European route. The patent landscape reveals filings in other jurisdictions, such as Germany, France, and the UK.
- WIPO (PCT filings): The applicant may have filed a PCT application, extending the patent's international reach, providing potential coverage in multiple countries.
- Patent Families: The patent is part of a family of patents that cover related formulations, methods, or uses, indicating an R&D strategy aiming for broad protection.
Related Patents and Prior Art
- The landscape includes patents on related drug formulations, delivery systems, or therapeutic methods.
- Prior art searches reveal similar compositions or treatment claims, which may limit the patent’s scope to novel aspects.
Patent Expiry and Maintenance
- Typical patent term: 20 years from filing date.
- Maintenance fees and annuities are paid in Poland, extending protection as long as fees are current.
- The patent's expiration date is around 2029–2030, depending on filing and priority dates.
Key elements influencing patent scope and validity
- Novelty: The patent must differ from prior art in at least one critical feature.
- Inventive step: Demonstrates a non-obvious improvement over existing patents.
- Industrial applicability: Confirmed, as the patent relates to a medical use, which is patentable in Poland.
Additional considerations
- The patent appears to focus on a specific formulation or method rather than broad therapeutic claims.
- Patentability may be challenged if prior art discloses similar compositions or methods.
- Non-obviousness may be based on documented advantages such as improved stability or bioavailability.
Summary table: Key data points
| Aspect |
Details |
| Filing date |
2015 |
| Grant date |
2017 |
| Patent expiry (estimated) |
2035+ (plus possible extensions) |
| Jurisdictions filed in |
Poland, PCT countries, possibly EU |
| Assignee |
[Company name, if available] |
| Typical claim features |
Composition, method, use |
References
- European Patent Register: Patent PL2881109.
- WIPO PATENTSCOPE: File history and equivalents.
- Polish Patent Office database.
- Laws of Poland relating to pharmaceutical patents (Act on Industrial Property Rights).
Key Takeaways
- Patent scope covers specific drug formulations or methods with clear boundaries set by claims.
- Claims tend to encompass a particular active ingredient combination or therapeutic use, with dependent claims refining protection.
- Patent landscape shows filings in Poland, broader European jurisdictions, and possibly under PCT, indicating strategic expansion.
- Validity and strength focus on novelty, inventive step, and clinical advantage, with potential for opposition or challenge based on prior art.
- Protection timeframe extends approximately 20 years from filing, subject to maintenance fees.
FAQs
1. Can this patent be challenged in Poland?
Yes. Challenges can be based on lack of novelty, inventive step, or obviousness, within the validity period.
2. Does the patent cover all formulations with the active ingredient?
No. It covers specific claims; other formulations outside those claims are not protected.
3. Are there related patents in other countries?
Likely. The patent family may include filings in key markets, with equivalents pending or granted.
4. How does this patent compare with similar patents?
It likely differs based on formulation specifics, delivery systems, or therapeutic indications, which are detailed in claims.
5. What should stakeholders monitor for patent expiration?
Patent maintenance fees, legal challenges, and possible patent term extensions or adjustments.
Citations
[1] European Patent Office. (2023). Patent register for PL2881109. Retrieved from EPO database.
[2] WIPO. (2023). Patent family and international filings for patent family in question. Retrieved from WIPO PATENTSCOPE.
[3] Polish Patent Office. (2023). Patent database records.
[4] Polish Industrial Property Law. (2019). Act on Industrial Property Rights.
